The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
 
Jennifer Ann Woyach
Consulting or Advisory Role - AstraZeneca; Beigene; Genentech; Janssen; Loxo; Newave Pharmaceutical; Pharmacyclics
Research Funding - Janssen; Karyopharm Therapeutics; MorphoSys; Schrodinger
 
Catherine Callaghan Coombs
Stock and Other Ownership Interests - Bluebird Bio; CTI BioPharma Corp
Honoraria - Abbvie; AstraZeneca; BeiGene; Genentech; H3 Biomedicine; Janssen; LOXO; MEI Pharma; MingSight; Novartis; Octapharm; Pharmacyclics; TG Therapeutics
Consulting or Advisory Role - Abbvie; Genentech; Lilly
Speakers' Bureau - Abbvie; BeiGene; Genentech
Research Funding - Loxo (Inst)
 
Katharine L. Lewis
Honoraria - AstraZeneca; Janssen; Roche
Consulting or Advisory Role - AstraZeneca; IQvia; Loxo/Lilly; Roche
Travel, Accommodations, Expenses - Janssen; Novartis
 
Maricer P. Escalon
Employment - Lilly O.
 
Matteo Ceccarelli
Employment - Loxo/Lilly
Stock and Other Ownership Interests - Lilly O.
Honoraria - Lilly O.
Travel, Accommodations, Expenses - Lilly O.
 
Yuanyuan Faith Bian
Employment - Lilly O.
 
William G. Wierda
Research Funding - Abbvie; Acerta Pharma/AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Kite, a Gilead Company; Loxo/Lilly; miRagen; Oncternal Therapeutics; Pharmacyclics; Sunesis Pharmaceuticals; Xencor